A study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in Advanced or Recurrent Endometrial Cancer in Spain

Trial Identifier: D9311L00001
Sponsor: AstraZeneca
Collaborator:
APICES Soluciones S.L.
Start Date: December 2024
Primary Completion Date: November 2028
Study Completion Date: November 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ES Alicante, ES, 03010
ES Barakaldo, ES, 48903
ES Barcelona, ES, 08035
ES Cordoba, ES, 14004
ES El Palmar, ES, 30120
ES Girona, ES, 17007
ES La Coruña, ES, 15006
ES Las Palmas de Gran Canaria, ES, 35016
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28046
ES Madrid, ES, 28041
ES Madrid, ES, 28034
ES Madrid, ES, 28807
ES Málaga, ES, 29010
ES Pamplona, ES, 31008
ES Salamanca, ES, 37007
ES San Sebastián, ES, 20014
ES Santander, ES, 39008
ES Sevilla, ES, 41013
ES Valencia, ES, 46010
ES Valencia, ES, 46026
ES Valencia, ES, 46009
ES Vigo, ES, 36312
ES Zaragoza, ES, 50009